Poster number |
Title |
Submitting author |
City and Country |
280 |
GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY |
Caroline Besson |
Le Chesnay, France |
281 |
Cardiotoxicity risk in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure |
Michael Buege |
New York, NY, USA |
282 |
Burden of lymphoma in China, 1990−2019: an analysis of Global Burden of Diseases, Injuries, and Risk Factors Study 2019 |
Weiping Liu |
Beijing, China |
283 |
Impact of the COVID-19 pandemic on the diagnosis of mature lymphoid neoplasms in Belgium: Results from the Belgian Cancer Registry |
Hélène Antoine-Poirel |
Brussels, Belgium |
284 |
Impaired humoral response in lymphoma patients surviving the acute phase of Covid-19 |
Chiara Cattaneo |
Brescia, Italy |
285 |
Multicenter retrospective analysis of risk factors for mortality of COVID-19 infection in patients with lymphoma. |
Jan Kořen |
Prague, Czech Republic |
286 |
Outcomes of patients with lymphoma and COVID-19: An observational cohort study from GELTAMO Spanish group |
Alejandro Martín García-Sancho |
Salamanca, Spain |
286 bis |
Serological responses after SARS-CoV-2 vaccination first dose in patients with lymphoid malignancy: first interim analysis of the UK PROSECO study |
Sean H. Lim |
Southampton, UK |
287 |
Efficacy and safety of daratumumab for the treatment of multiple myeloma: a series of cochrane reviews |
Caroline Hirsch |
Cologne, Germany |